Labcorp Has a Diagnostics-and-Biopharma Cash Engine Bigger Than the Post-COVID Testing Narrative

[ad_1] Labcorp’s latest quarter showed a business that is no longer usefully described through the lens of COVID-era distortion. For the quarter ended March 31, 2026, revenue increased 5.8% year over year to $3.54 billion, while adjusted EPS rose 10.6%…







